Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo

ACT‐1014‐6470 is an orally available complement factor 5a receptor 1 antagonist and a novel treatment option in auto‐inflammatory diseases. The in vitro inhibition potential of ACT‐1014‐6470 on cytochrome P450 isozymes (CYPs) and its effect on the pharmacokinetics (PK) of the CYP2C19 and CYP3A4 subs...

Descripción completa

Detalles Bibliográficos
Autores principales: Anliker‐Ort, Marion, Dingemanse, Jasper, Delahaye, Stephane, Janů, Luboš, van den Anker, John, Berger, Benjamin, Kaufmann, Priska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339695/
https://www.ncbi.nlm.nih.gov/pubmed/37042126
http://dx.doi.org/10.1111/cts.13525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339695/
https://www.ncbi.nlm.nih.gov/pubmed/37042126
http://dx.doi.org/10.1111/cts.13525

Ejemplares similares